Study of staying on PCSK9 injections and health outcomes
Part of Hormones & metabolism clinical trials.
This study follows people who are already taking PCSK9 inhibitor shots to see how well patients stay on treatment and how effective it is. Your participation would mainly be about consenting to provide basic information and possibly follow-up details.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking a PCSK9 inhibitor medication (injection).
- You must be between 18 and 80 years old.
- You must be willing to participate in the study.
- You must sign informed consent (agree to join).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a cholesterol-lowering injection (alirocumab) helps people who are on regular dialysis. It aims to improve cholesterol control in a carefully selected group and tracks safety during treatment.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
This study looks at how a natural enzyme in the body, called PCSK9, affects blood platelets. It compares healthy people to those with heart risk factors to see if the enzyme changes how platelets work.
This trial tests a new medicine, SHR-1918, for people whose bad cholesterol (LDL-C) stays high even when they take statins and another type of cholesterol-lowering drug called a PCSK9 inhibitor. It aims to see if this additional treatment can lower their cholesterol more effectively.
This trial tests whether giving a cholesterol-lowering injection (called a PCSK9 inhibitor) early after a stroke helps improve recovery and lowers cholesterol. It is for people whose stroke is caused by narrowed arteries, not by heart problems.
This study looks at how well two cholesterol-lowering medicines, evolocumab and alirocumab, work in people with high cholesterol or heart disease. It reviews medical records from patients at a specific hospital to see how these medicines affect cholesterol levels.
Hear when a new Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.